ARTICLE | Emerging Company Profile
RORing against resistance
Why Oncternal’s ROR1 inhibitor could pair with BTK in chemo-resistant cancers
October 24, 2016 7:00 AM UTC
Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma.
The Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica ibrutinib from AbbVie Inc. and Johnson & Johnson is used to treat CLL and MCL after chemotherapy fails. ...
BCIQ Target Profiles